Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Home Continuous Antibiotic Infusion (TAID)
NCT04816968Phase 1Unknown
- Sponsor
- Ospedale San Carlo Borromeo
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Reversible Covalent Inhibitors, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of cefepime, piperacillin + tazobactam, meropenem and vancomycin in bacterial infection (4 arms), sponsored by Ospedale San Carlo Borromeo. Primary endpoint: Number of hospitalization days for the treatment of severe bacterial infections at 14 days. Status: unknown.
02
Drugs
cefepimepiperacillin + tazobactammeropenemvancomycin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04816968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816968.